In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020

Yu Lin Lee; Wen Chien Ko; Wen Sen Lee; Po Liang Lu; Yen Hsu Chen; Shu Hsing Cheng; Min Chi Lu; Chi Ying Lin; Ting Shu Wu; Muh Yong Yen; Lih Shinn Wang; Chang Pan Liu; Pei Lan Shao; Zhi Yuan Shi; Yao Shen Chen; Fu Der Wang; Shu Hui Tseng; Chao Nan Lin; Yu Hui Chen; Wang Huei Sheng; Chun Ming Lee; Hung Jen Tang; Po Ren Hsueh

doi:10.1016/j.ijantimicag.2021.106377

In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020

Yu Lin Lee, Wen Chien Ko, Wen Sen Lee, Po Liang Lu, Yen Hsu Chen, Shu Hsing Cheng, Min Chi Lu, Chi Ying Lin, Ting Shu Wu, Muh Yong Yen, Lih Shinn Wang, Chang Pan Liu, Pei Lan Shao, Zhi Yuan Shi, Yao Shen Chen, Fu Der Wang, Shu Hui Tseng, Chao Nan Lin, Yu Hui Chen, Wang Huei ShengChun Ming Lee, Hung Jen Tang, Po Ren Hsueh

內科學科

研究成果: Article › 同行評審

19 引文斯高帕斯（Scopus）

摘要

This study examined the susceptibility of carbapenem-nonsusceptible Enterobacterales (CNSE) to cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents. Non-duplicate Enterobacterales isolates from 16 Taiwanese hospitals were evaluated. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibility results were interpreted based on relevant guidelines. In total, 201 CNSE isolates were investigated, including 26 Escherichia coli isolates and 175 Klebsiella pneumoniae isolates. Carbapenemase genes were detected in 15.4% (n=4) of E. coli isolates and 47.4% (n=83) of K. pneumoniae isolates, with the most common being bla_KPC (79.3%, 69/87), followed by bla_OXA-48-like (13.8%, 12/87). Cefiderocol was the most active agent against CNSE; only 3.8% (n=1) of E. coli isolates and 4.6% (n=8) of K. pneumoniae isolates were not susceptible to cefiderocol. Among the carbapenem-resistant E. coli and K. pneumoniae isolates, 88.5% (n=23) and 93.7% (n=164), respectively, were susceptible to ceftazidime/avibactam. For cefepime/zidebactam, 23 (88.5%) E. coli isolates and 155 (88.6%) K. pneumoniae isolates had MICs ≤2/2 mg/L. For cefepime/enmetazobactam, 22 (84.6%) E. coli isolates and 85 (48.6%) K. pneumoniae isolates had MICs ≤2/8 mg/L. The higher MICs of K. pneumoniae against cefepime/enmetazobactam were due to only one (1.5%) of the 67 bla_KPC-carrying isolates being susceptible. MICs of omadacycline were significantly higher than those of eravacycline and tigecycline. In summary, cefiderocol, ceftazidime/avibactam and cefepime/zidebactam were more effective against carbapenem-nonsusceptible E. coli and K. pneumoniae than other drugs, highlighting their potential as valuable therapeutics.

原文	English
文章編號	106377
期刊	International journal of antimicrobial agents
卷	58
發行號	3
DOIs	https://doi.org/10.1016/j.ijantimicag.2021.106377
出版狀態	Published - 2021 9月

All Science Journal Classification (ASJC) codes

微生物學（醫學）
傳染性疾病
藥學（醫學）

存取文件

10.1016/j.ijantimicag.2021.106377

其它文件與鏈接

指紋

深入研究「In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020」主題。共同形成了獨特的指紋。

引用此

Lee, Y. L., Ko, W. C., Lee, W. S., Lu, P. L., Chen, Y. H., Cheng, S. H., Lu, M. C., Lin, C. Y., Wu, T. S., Yen, M. Y., Wang, L. S., Liu, C. P., Shao, P. L., Shi, Z. Y., Chen, Y. S., Wang, F. D., Tseng, S. H., Lin, C. N., Chen, Y. H., ... Hsueh, P. R. (2021). In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020. International journal of antimicrobial agents, 58(3), 文章 106377. https://doi.org/10.1016/j.ijantimicag.2021.106377

Lee, Yu Lin ; Ko, Wen Chien ; Lee, Wen Sen 等. / In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales : results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020. 於: International journal of antimicrobial agents. 2021 ; 卷 58, 編號 3.

@article{29a00c870cff41e49836863f0234b76f,

title = "In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020",

abstract = "This study examined the susceptibility of carbapenem-nonsusceptible Enterobacterales (CNSE) to cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents. Non-duplicate Enterobacterales isolates from 16 Taiwanese hospitals were evaluated. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibility results were interpreted based on relevant guidelines. In total, 201 CNSE isolates were investigated, including 26 Escherichia coli isolates and 175 Klebsiella pneumoniae isolates. Carbapenemase genes were detected in 15.4% (n=4) of E. coli isolates and 47.4% (n=83) of K. pneumoniae isolates, with the most common being blaKPC (79.3%, 69/87), followed by blaOXA-48-like (13.8%, 12/87). Cefiderocol was the most active agent against CNSE; only 3.8% (n=1) of E. coli isolates and 4.6% (n=8) of K. pneumoniae isolates were not susceptible to cefiderocol. Among the carbapenem-resistant E. coli and K. pneumoniae isolates, 88.5% (n=23) and 93.7% (n=164), respectively, were susceptible to ceftazidime/avibactam. For cefepime/zidebactam, 23 (88.5%) E. coli isolates and 155 (88.6%) K. pneumoniae isolates had MICs ≤2/2 mg/L. For cefepime/enmetazobactam, 22 (84.6%) E. coli isolates and 85 (48.6%) K. pneumoniae isolates had MICs ≤2/8 mg/L. The higher MICs of K. pneumoniae against cefepime/enmetazobactam were due to only one (1.5%) of the 67 blaKPC-carrying isolates being susceptible. MICs of omadacycline were significantly higher than those of eravacycline and tigecycline. In summary, cefiderocol, ceftazidime/avibactam and cefepime/zidebactam were more effective against carbapenem-nonsusceptible E. coli and K. pneumoniae than other drugs, highlighting their potential as valuable therapeutics.",

author = "Lee, {Yu Lin} and Ko, {Wen Chien} and Lee, {Wen Sen} and Lu, {Po Liang} and Chen, {Yen Hsu} and Cheng, {Shu Hsing} and Lu, {Min Chi} and Lin, {Chi Ying} and Wu, {Ting Shu} and Yen, {Muh Yong} and Wang, {Lih Shinn} and Liu, {Chang Pan} and Shao, {Pei Lan} and Shi, {Zhi Yuan} and Chen, {Yao Shen} and Wang, {Fu Der} and Tseng, {Shu Hui} and Lin, {Chao Nan} and Chen, {Yu Hui} and Sheng, {Wang Huei} and Lee, {Chun Ming} and Tang, {Hung Jen} and Hsueh, {Po Ren}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = sep,

doi = "10.1016/j.ijantimicag.2021.106377",

language = "English",

volume = "58",

journal = "International journal of antimicrobial agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "3",

}

Lee, YL, Ko, WC, Lee, WS, Lu, PL, Chen, YH, Cheng, SH, Lu, MC, Lin, CY, Wu, TS, Yen, MY, Wang, LS, Liu, CP, Shao, PL, Shi, ZY, Chen, YS, Wang, FD, Tseng, SH, Lin, CN, Chen, YH, Sheng, WH, Lee, CM, Tang, HJ & Hsueh, PR 2021, 'In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020', International journal of antimicrobial agents, 卷 58, 編號 3, 106377. https://doi.org/10.1016/j.ijantimicag.2021.106377

In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020. / Lee, Yu Lin; Ko, Wen Chien; Lee, Wen Sen 等.
於: International journal of antimicrobial agents, 卷 58, 編號 3, 106377, 09.2021.

研究成果: Article › 同行評審

TY - JOUR

T1 - In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales

T2 - results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020

AU - Lee, Yu Lin

AU - Ko, Wen Chien

AU - Lee, Wen Sen

AU - Lu, Po Liang

AU - Chen, Yen Hsu

AU - Cheng, Shu Hsing

AU - Lu, Min Chi

AU - Lin, Chi Ying

AU - Wu, Ting Shu

AU - Yen, Muh Yong

AU - Wang, Lih Shinn

AU - Liu, Chang Pan

AU - Shao, Pei Lan

AU - Shi, Zhi Yuan

AU - Chen, Yao Shen

AU - Wang, Fu Der

AU - Tseng, Shu Hui

AU - Lin, Chao Nan

AU - Chen, Yu Hui

AU - Sheng, Wang Huei

AU - Lee, Chun Ming

AU - Tang, Hung Jen

AU - Hsueh, Po Ren

PY - 2021/9

Y1 - 2021/9

N2 - This study examined the susceptibility of carbapenem-nonsusceptible Enterobacterales (CNSE) to cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents. Non-duplicate Enterobacterales isolates from 16 Taiwanese hospitals were evaluated. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibility results were interpreted based on relevant guidelines. In total, 201 CNSE isolates were investigated, including 26 Escherichia coli isolates and 175 Klebsiella pneumoniae isolates. Carbapenemase genes were detected in 15.4% (n=4) of E. coli isolates and 47.4% (n=83) of K. pneumoniae isolates, with the most common being blaKPC (79.3%, 69/87), followed by blaOXA-48-like (13.8%, 12/87). Cefiderocol was the most active agent against CNSE; only 3.8% (n=1) of E. coli isolates and 4.6% (n=8) of K. pneumoniae isolates were not susceptible to cefiderocol. Among the carbapenem-resistant E. coli and K. pneumoniae isolates, 88.5% (n=23) and 93.7% (n=164), respectively, were susceptible to ceftazidime/avibactam. For cefepime/zidebactam, 23 (88.5%) E. coli isolates and 155 (88.6%) K. pneumoniae isolates had MICs ≤2/2 mg/L. For cefepime/enmetazobactam, 22 (84.6%) E. coli isolates and 85 (48.6%) K. pneumoniae isolates had MICs ≤2/8 mg/L. The higher MICs of K. pneumoniae against cefepime/enmetazobactam were due to only one (1.5%) of the 67 blaKPC-carrying isolates being susceptible. MICs of omadacycline were significantly higher than those of eravacycline and tigecycline. In summary, cefiderocol, ceftazidime/avibactam and cefepime/zidebactam were more effective against carbapenem-nonsusceptible E. coli and K. pneumoniae than other drugs, highlighting their potential as valuable therapeutics.

AB - This study examined the susceptibility of carbapenem-nonsusceptible Enterobacterales (CNSE) to cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents. Non-duplicate Enterobacterales isolates from 16 Taiwanese hospitals were evaluated. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method, and susceptibility results were interpreted based on relevant guidelines. In total, 201 CNSE isolates were investigated, including 26 Escherichia coli isolates and 175 Klebsiella pneumoniae isolates. Carbapenemase genes were detected in 15.4% (n=4) of E. coli isolates and 47.4% (n=83) of K. pneumoniae isolates, with the most common being blaKPC (79.3%, 69/87), followed by blaOXA-48-like (13.8%, 12/87). Cefiderocol was the most active agent against CNSE; only 3.8% (n=1) of E. coli isolates and 4.6% (n=8) of K. pneumoniae isolates were not susceptible to cefiderocol. Among the carbapenem-resistant E. coli and K. pneumoniae isolates, 88.5% (n=23) and 93.7% (n=164), respectively, were susceptible to ceftazidime/avibactam. For cefepime/zidebactam, 23 (88.5%) E. coli isolates and 155 (88.6%) K. pneumoniae isolates had MICs ≤2/2 mg/L. For cefepime/enmetazobactam, 22 (84.6%) E. coli isolates and 85 (48.6%) K. pneumoniae isolates had MICs ≤2/8 mg/L. The higher MICs of K. pneumoniae against cefepime/enmetazobactam were due to only one (1.5%) of the 67 blaKPC-carrying isolates being susceptible. MICs of omadacycline were significantly higher than those of eravacycline and tigecycline. In summary, cefiderocol, ceftazidime/avibactam and cefepime/zidebactam were more effective against carbapenem-nonsusceptible E. coli and K. pneumoniae than other drugs, highlighting their potential as valuable therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85110462352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110462352&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2021.106377

DO - 10.1016/j.ijantimicag.2021.106377

M3 - Article

C2 - 34166777

AN - SCOPUS:85110462352

SN - 0924-8579

VL - 58

JO - International journal of antimicrobial agents

JF - International journal of antimicrobial agents

IS - 3

M1 - 106377

ER -

Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH 等. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020. International journal of antimicrobial agents. 2021 9月;58(3):106377. doi: 10.1016/j.ijantimicag.2021.106377